The Use of Clobazam as Add-on Treatment in Resistant Epilepsy: Our Retrospective Clinical Data
TURKISH JOURNAL OF NEUROLOGY, vol.26, no.1, pp.10-13, 2020 (ESCI, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 26 Issue: 1
- Publication Date: 2020
- Doi Number: 10.4274/tnd.galenos.2019.22755
- Journal Name: TURKISH JOURNAL OF NEUROLOGY
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Page Numbers: pp.10-13
- Istanbul University-Cerrahpasa Affiliated: No
Abstract
Objective: Patients with drug-resistant focal or generalized epilepsy are important in terms of treatment and polytherapy necessity, adverse effect profiles of drugs, and seizure control difficulties. Clobazam (CLB), which has a lesser sedative effect than other benzodiazepines, is frequently used in different countries. In this study, we aimed to present the results related to the demographic characteristics, adverse effects, and treatment efficacy of patients under CLB treatment.